Limits...
Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth.

Hu J, Meng Y, Yu T, Hu L, Mao M - Oncotarget (2015)

Bottom Line: We found that expression of MARCH7 was higher in ovarian cancer tissues than normal ovarian tissues.Finally, MARCH7 was regulated by miR-101.Thus, MARCH7 is oncogenic and a potential target (oncotarget) for ovarian cancer therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

ABSTRACT
Ubiquitin E3 ligase MARCH7 is involved in T cell proliferation and neuronal development. We found that expression of MARCH7 was higher in ovarian cancer tissues than normal ovarian tissues. Silencing MARCH7 decreased cell proliferation, migration, and invasion. Ectopic expression of MARCH7 increased cell proliferation, migration and invasion. Silencing MARCH7 prevented ovarian cancer growth in mice. Silencing MARCH7 inhibited NFkB and Wnt/β-catenin pathway. In agreement, ectopically expressed MARCH7 activated NFkB and Wnt/β-catenin pathways. Finally, MARCH7 was regulated by miR-101. Thus, MARCH7 is oncogenic and a potential target (oncotarget) for ovarian cancer therapy.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical analysis of MARCH7 expression in ovarian cancerMARCH7 was predominantly localized in the (A) plasma membrane, (B, C, D, E) cytoplasm. The expression of MARCH7 in different types of ovarian cancer samples. (A). serous papillary adenocarcinoma (stage I); (B). serous papillary adenocarcinoma (stage IIIA); (C). serous papillary adenocarcinoma (stage IIIC); (D). mucinous adenocarcinoma mucinous adenocarcinoma (stage IA); (E). mucinous adenocarcinoma mucinous adenocarcinoma (stage IB) ; (F). mucinous adenocarcinoma mucinous adenocarcinoma (stage III); (G). endometrioid adenocarcinoma(stage I); (H). endometrioid adenocarcinoma(stage III); (I). normal ovarian tissue. Original magnification, 200X.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494930&req=5

Figure 1: Immunohistochemical analysis of MARCH7 expression in ovarian cancerMARCH7 was predominantly localized in the (A) plasma membrane, (B, C, D, E) cytoplasm. The expression of MARCH7 in different types of ovarian cancer samples. (A). serous papillary adenocarcinoma (stage I); (B). serous papillary adenocarcinoma (stage IIIA); (C). serous papillary adenocarcinoma (stage IIIC); (D). mucinous adenocarcinoma mucinous adenocarcinoma (stage IA); (E). mucinous adenocarcinoma mucinous adenocarcinoma (stage IB) ; (F). mucinous adenocarcinoma mucinous adenocarcinoma (stage III); (G). endometrioid adenocarcinoma(stage I); (H). endometrioid adenocarcinoma(stage III); (I). normal ovarian tissue. Original magnification, 200X.

Mentions: The expression profile of MARCH 7 in ovarian cancer is not yet fully elucidated. We examined the expression pattern of MARCH7 in normal ovary and ovarian cancer tissue samples using IHC. The expression of MARCH7 was significantly higher in ovarian carcinoma samples than that in normal ovarian samples (Fig. 1 and Table 1). MARCH7 was predominantly localized on the plasma membrane, and cytoplasm (Fig. 1A-H). MARCH7 expression was significantly higher in epithelial ovarian cancer samples than that in normal ovary tissues (P < 0.05; Table 1). To determine the correlation of MARCH7 expression with cancer type and cancer stage, all cancer samples were grouped into histologic types (serous papillary adenocarcinoma, mucinous adenocarcinoma, and endometrioid adenocarcinoma) (Fig. 1A-H). The differently expression of MARCH7 between serous adenocarcinoma and other histologic type of the tumor was not significant (P>0.05). MARCH7 immunostaining was significantly higher in tumor samples in advanced stages (stage III/IV) as compared to those in the early stages (stage I/II) disease (P < 0.01). Further, the staining intensity significantly correlated with the tumor grade (grades 2–3 versus 1, P < 0.01). However, the associations between MARCH7 expression and age were not significant (P > 0.05; Table 1).


Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth.

Hu J, Meng Y, Yu T, Hu L, Mao M - Oncotarget (2015)

Immunohistochemical analysis of MARCH7 expression in ovarian cancerMARCH7 was predominantly localized in the (A) plasma membrane, (B, C, D, E) cytoplasm. The expression of MARCH7 in different types of ovarian cancer samples. (A). serous papillary adenocarcinoma (stage I); (B). serous papillary adenocarcinoma (stage IIIA); (C). serous papillary adenocarcinoma (stage IIIC); (D). mucinous adenocarcinoma mucinous adenocarcinoma (stage IA); (E). mucinous adenocarcinoma mucinous adenocarcinoma (stage IB) ; (F). mucinous adenocarcinoma mucinous adenocarcinoma (stage III); (G). endometrioid adenocarcinoma(stage I); (H). endometrioid adenocarcinoma(stage III); (I). normal ovarian tissue. Original magnification, 200X.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494930&req=5

Figure 1: Immunohistochemical analysis of MARCH7 expression in ovarian cancerMARCH7 was predominantly localized in the (A) plasma membrane, (B, C, D, E) cytoplasm. The expression of MARCH7 in different types of ovarian cancer samples. (A). serous papillary adenocarcinoma (stage I); (B). serous papillary adenocarcinoma (stage IIIA); (C). serous papillary adenocarcinoma (stage IIIC); (D). mucinous adenocarcinoma mucinous adenocarcinoma (stage IA); (E). mucinous adenocarcinoma mucinous adenocarcinoma (stage IB) ; (F). mucinous adenocarcinoma mucinous adenocarcinoma (stage III); (G). endometrioid adenocarcinoma(stage I); (H). endometrioid adenocarcinoma(stage III); (I). normal ovarian tissue. Original magnification, 200X.
Mentions: The expression profile of MARCH 7 in ovarian cancer is not yet fully elucidated. We examined the expression pattern of MARCH7 in normal ovary and ovarian cancer tissue samples using IHC. The expression of MARCH7 was significantly higher in ovarian carcinoma samples than that in normal ovarian samples (Fig. 1 and Table 1). MARCH7 was predominantly localized on the plasma membrane, and cytoplasm (Fig. 1A-H). MARCH7 expression was significantly higher in epithelial ovarian cancer samples than that in normal ovary tissues (P < 0.05; Table 1). To determine the correlation of MARCH7 expression with cancer type and cancer stage, all cancer samples were grouped into histologic types (serous papillary adenocarcinoma, mucinous adenocarcinoma, and endometrioid adenocarcinoma) (Fig. 1A-H). The differently expression of MARCH7 between serous adenocarcinoma and other histologic type of the tumor was not significant (P>0.05). MARCH7 immunostaining was significantly higher in tumor samples in advanced stages (stage III/IV) as compared to those in the early stages (stage I/II) disease (P < 0.01). Further, the staining intensity significantly correlated with the tumor grade (grades 2–3 versus 1, P < 0.01). However, the associations between MARCH7 expression and age were not significant (P > 0.05; Table 1).

Bottom Line: We found that expression of MARCH7 was higher in ovarian cancer tissues than normal ovarian tissues.Finally, MARCH7 was regulated by miR-101.Thus, MARCH7 is oncogenic and a potential target (oncotarget) for ovarian cancer therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

ABSTRACT
Ubiquitin E3 ligase MARCH7 is involved in T cell proliferation and neuronal development. We found that expression of MARCH7 was higher in ovarian cancer tissues than normal ovarian tissues. Silencing MARCH7 decreased cell proliferation, migration, and invasion. Ectopic expression of MARCH7 increased cell proliferation, migration and invasion. Silencing MARCH7 prevented ovarian cancer growth in mice. Silencing MARCH7 inhibited NFkB and Wnt/β-catenin pathway. In agreement, ectopically expressed MARCH7 activated NFkB and Wnt/β-catenin pathways. Finally, MARCH7 was regulated by miR-101. Thus, MARCH7 is oncogenic and a potential target (oncotarget) for ovarian cancer therapy.

No MeSH data available.


Related in: MedlinePlus